English press releases

SES and Quvia to Codevelop New-Generation Multi-Orbit Solutions to Enhance Quality of Experience

New partnership combines SES and Quvia’s expertise in technology and innovation for improved network delivery and optimisation in multiple market segments, powered by artificial intelligence...

IFF Announces Executive Leadership Team Aligned With New Operating Model

NEW YORK–(BUSINESS WIRE)– IFF (NYSE: IFF) announced changes to its executive leadership team, aligned with the Company’s external reporting structure. After 21 years of dedicated...

NTT DATA Launches Smart AI Agent™ to Accelerate Generative AI Adoption and Drive $2 Billion in Revenue by 2027

Next-generation AI tool will enhance operational efficiency, address global talent shortages, and empower businesses with smarter automation. TOKYO–(BUSINESS WIRE)– NTT DATA, a global digital business...

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Innovative Technology Allows Clinicians to Target and Acquire Tissue Samples Using Contrast-Enhanced Mammography MARLBOROUGH, Mass.–(BUSINESS WIRE)– Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today...

DIA Europe 2025 to Address EU Regulatory Reforms and How to Advance Global Healthcare Harmonization

Experts will explore AI-driven healthcare innovation and strategies to enhance patient engagement BASEL, Switzerland–(BUSINESS WIRE)– DIA, a global non-profit organization of life sciences professionals, will...

HSBC Continental Europe: 2024 Annual and Second Half Results

PARIS–(BUSINESS WIRE)– Regulatory News: On 18 February 2025, HSBC Continental Europe’s Board of Directors reviewed the second half year results and approved the consolidated financial...

SES Enables Viasat Energy Services’ Asia-Pacific Customer to Experience High-Performance Connectivity

SES’s O3b mPOWER enhances offshore operations with high-performance connectivity to a Floating Production Storage and Offloading (FPSO) vessel LUXEMBOURG–(BUSINESS WIRE)– SES announced today that O3b...

IFF Reports Fourth Quarter and Full Year 2024 Results

NEW YORK–(BUSINESS WIRE)– International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2024. Management...

SES Market Update in Context of Moody’s Ratings Press Release

LUXEMBOURG–(BUSINESS WIRE)– SES S.A. has taken note of Moody’s Ratings Press Release today with regards to SES and is providing a market update ahead of...

Bluefin Achieves Girocard Certification for the Newland Payment Technology N950 AIO smartPOS

ATLANTA & VIENNA–(BUSINESS WIRE)– Bluefin has achieved the German Banking Industry Committee’s (GBIC German: Deutsche Kreditwirtschaft) Girocard certification on the Newland NPT N950 AIO smartPOS...

KKR Enters Into Strategic Partnership With Energy Service Provider EGC

FRANKFURT, Germany–(BUSINESS WIRE)– KKR, a leading global investment firm, announced that KKR has signed agreements to enter into a strategic partnership with EGC, an energy...

Novotech Partners with Wonju Severance Christian Hospital to Drive Clinical Research Excellence in Korea

SEOUL, South Korea–(BUSINESS WIRE)– Novotech, a global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate...

Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis

These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the remaining countries – Australia...

ATP Media Selects SES for Tennis Content Delivery Worldwide

SES SCORE platform and hybrid distribution to power broadcasts of 58 ATP tournaments that reach a billion global fans through 70+ broadcast partners LUXEMBOURG–(BUSINESS WIRE)–...

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

In the MOTION Phase 3 study, ROMVIMZA met primary endpoint of improved objective response rate (ORR) compared to placebo and all key secondary endpoints with...